Cargando…
Patient Surveillance After Cancer Treatment
Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of va...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , , , , , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2013.
|
| Edición: | 1st ed. 2013. |
| Colección: | Current Clinical Oncology,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-60327-969-7 | ||
| 003 | DE-He213 | ||
| 005 | 20220116215051.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 130321s2013 xxu| s |||| 0|eng d | ||
| 020 | |a 9781603279697 |9 978-1-60327-969-7 | ||
| 024 | 7 | |a 10.1007/978-1-60327-969-7 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Patient Surveillance After Cancer Treatment |h [electronic resource] / |c edited by Frank E Johnson, Yoshihiko Maehara, George P Browman, Julie A. Margenthaler, Riccardo A. Audisio, John F Thompson, David Y. Johnson, Craig C. Earle, Katherine S. Virgo. |
| 250 | |a 1st ed. 2013. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2013. | |
| 300 | |a XXI, 538 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Current Clinical Oncology, |x 2364-1142 | |
| 505 | 0 | |a 1. Overview -- 2. Introduction to Cancer Surveillance Strategies -- 3. Using Decision Analysis to Model Cancer Surveillance -- 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment -- 5. Upper Aerodigestive Tract Carcinoma -- 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe -- 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan -- 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada -- 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma -- 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia -- 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan -- 12. Lung Carcinoma -- 13. Lung Carcinoma Surveillance Counterpoint: Australia -- 14. Lung Carcinoma Surveillance Counterpoint: Japan -- 15. Lung Carcinoma Surveillance Counterpoint: Canada -- 16. Esophagus Carcinoma -- 17. Esophagus Carcinoma Surveillance Counterpoint: Australia -- 18. Esophagus Carcinoma Surveillance Counterpoint: Japan -- 19. Stomach -- 20. Stomach Carcinoma Surveillance Counterpoint: USA -- 21. Stomach Carcinoma Surveillance Counterpoint: Japan -- 22. Pancreatic Adenocarcinoma -- 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA -- 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe -- 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan -- 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada -- 27. Liver and Biliary Tract Carcinoma -- 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe -- 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia -- 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan -- 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada -- 32. Colon and Rectum Carcinoma -- 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA -- 34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia -- 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan -- 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada -- 37. Anal Carcinoma -- 38. Anal Carcinoma Surveillance Counterpoint: USA -- 39. Anal Carcinoma Surveillance Counterpoint: Australia -- 40. Anal Carcinoma Surveillance Counterpoint: Japan -- 41. Anal Carcinoma Surveillance Counterpoint: Canada -- 42. Soft Tissue Sarcoma -- 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA -- 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan -- 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada -- 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma -- 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan -- 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada -- 49. Cutaneous Melanoma -- 50. Cutaneous Melanoma Surveillance Counterpoint: USA -- 51. Cutaneous Melanoma Surveillance Counterpoint: Australia -- 52. Cutaneous Melanoma Surveillance Counterpoint: Japan -- 53. Breast Carcinoma -- 54. Breast Carcinoma Surveillance Counterpoint: USA -- 55. Breast Carcinoma Surveillance Counterpoint: Europe -- 56. Breast Carcinoma Surveillance Counterpoint: Australia -- 57. Breast Carcinoma Surveillance Counterpoint: Japan -- 58. Endometrial Carcinoma -- 59. Endometrial Cancer Surveillance Counterpoint: USA -- 60. Endometrial Cancer Surveillance Counterpoint: USA -- 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan -- 62. Endometrial Carcinoma Surveillance Counterpoint: Canada -- 63. Cervical Carcinoma -- 64. Cervical Carcinoma Surveillance Counterpoint: USA -- 65. Cervical Carcinoma Surveillance Counterpoint: Japan -- 66. Cervical Carcinoma Surveillance Counterpoint: Canada -- 67. Vaginal and Vulvar Carcinoma -- 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan -- 69. Ovarian Carcinoma -- 70. Ovarian Carcinoma Surveillance Counterpoint: USA -- 71. Ovarian Cancer Surveillance Counterpoint: Europe -- 72. Ovarian Cancer Surveillance Counterpoint: Japan -- 73. Renal Carcinoma -- 74. Renal Carcinoma Surveillance Counterpoint: Europe -- 75. Renal Carcinoma Surveillance Counterpoint: Japan -- 76. Renal Carcinoma Surveillance Counterpoint: Canada -- 77. Urinary Bladder Carcinoma -- 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan -- 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada -- 80. Prostate Carcinoma -- 81. Prostate Carcinoma Surveillance Counterpoint: USA -- 82. Prostate Carcinoma Surveillance Counterpoint: USA -- 83. Prostate Carcinoma Surveillance Counterpoint: Europe -- 84. Prostate Carcinoma Surveillance Counterpoint: Japan -- 85. Prostate Carcinoma Surveillance Counterpoint: Canada -- 86. Testicle Carcinoma -- 87. Testicle Carcinoma Surveillance Counterpoint: USA -- 88. Testicle Carcinoma Surveillance Counterpoint: Australia -- 89. Testicle Carcinoma Surveillance Counterpoint: Japan -- 90. Lymphoma -- 91. Lymphoma Surveillance Counterpoint: USA -- 92. Lymphoma Surveillance Counterpoint: Japan -- 93. Lymphoma (Following Autologous Stem Cell Transplant) -- 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan -- 95. Leukemia -- 96. Leukemia Surveillance Counterpoint: USA -- 97. Leukemia Surveillance Counterpoint: Japan -- 98. Multiple Myeloma -- 99. Multiple Myeloma Surveillance Counterpoint: USA -- 100. Multiple Myeloma Surveillance Counterpoint: Australia -- 101. Multiple Myeloma Surveillance Counterpoint: Japan -- 102. Multiple Myeloma Surveillance Counterpoint: Canada -- 103. Glioma of the Central Nervous System -- 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe -- 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia -- 106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan. . | |
| 520 | |a Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer. The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients. This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today's practicing oncologist. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Cancer-Treatment. | |
| 650 | 0 | |a Radiology. | |
| 650 | 0 | |a Cancer. | |
| 650 | 1 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Cancer Therapy. |
| 650 | 2 | 4 | |a Radiology. |
| 650 | 2 | 4 | |a Cancer Biology. |
| 700 | 1 | |a Johnson, Frank E. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Maehara, Yoshihiko. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Browman, George P. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Margenthaler, Julie A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Audisio, Riccardo A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Thompson, John F. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Johnson, David Y. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Earle, Craig C. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Virgo, Katherine S. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781607610021 |
| 776 | 0 | 8 | |i Printed edition: |z 9781603279680 |
| 776 | 0 | 8 | |i Printed edition: |z 9781627039659 |
| 830 | 0 | |a Current Clinical Oncology, |x 2364-1142 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-60327-969-7 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||